生物人工肝用C3A细胞在零下非结冰时的保存

目的:探讨零下非结冰保存肝细胞的效果及其与细胞凋亡的关系.方法:UW液保存的C3A细胞悬液分为3组:-0.8℃组(零下非结冰组),0℃组(0℃非结冰组),4℃组(对照组).低温保存24、48及72 h后,采用流式细胞术分别测定细胞存活率及凋亡率,同时测定LDH、乳酸释放,细胞内ATP含量、尿素合成功能及白蛋白分泌功能,同时观察细胞形态.结果:零下非结冰组较0℃非结冰组及对照组明显提高了低温保存72 h的C3A细胞的存活率(86.49%±2.80%vs 81.50%±2.83%.77.83%±3.40%,均P<0.05),降低了细胞凋亡率(1.26%±0.84%vs 5.34%±1.20%,9.16%±1.99%,均P<0.05);明显抑制了低温保存72 h乳酸以及LDH释放(乳酸:10.38μg/106 Cells±1.40 μg/106 cells vs 12.02 μg/106cells±1.64μg/106 cells,17.41μg/10°cells±2.40μg/106cells:LDH:80.10 U/L±11.10 U/L vs 12004U/L±14.32 U/L,148.98 U/L±15.37 U/L,均P<0.05);更好地维持了低温保存72 h C3A细胞内ATP含量、尿素合成功能、及白蛋白分泌功能(均P<0.05).形态上,零下非结冰组保存细胞死亡比例少,细胞接触良好,未见对照组及0℃非结冰组细胞膜周围出现"毛刺"样改变及细胞内的"空泡样"改变.结论:在零下非结冰条件下保存肝细胞,建立一个"血库样"(ready to use)肝细胞库,可以有效促进生物人工肝的发展.     

零下非结冰保存L-02细胞的效果及与细胞凋亡的关系

目的 采用UW液零下非结冰(-0.8℃)保存生物人工肝用L-02细胞,与常规低温(4℃及0℃)比较,探索零下非结冰保存肝细胞的效果以及同细胞凋亡的关系.方法 制备好的UW液保存的L-02细胞悬液分为3组:-0.8℃组(零下非结冰组),0℃组(0℃非结冰组),4℃组(对照组).低温保存24 h、48 h及72 h后,分别测定细胞存活率及凋亡率(流式细胞术)、LDH释放、尿素合成功能、白蛋白分泌功能.结果 零下非结冰(-0.8℃)较常规低温(0℃及4℃)明显提高了低温保存L-02细胞的存活率[72 h:-0.8℃(70.17±2.82)% vs 4℃(60.05±3.17)%],降低了细胞凋亡率[72 h:-0.8℃(5.73±1.68)% vs 4℃(9.20±2.35)%].零下非结冰明显抑制了LDH的释放[72 h:-0.8℃(113.88±5.64)U/L vs 4℃(170.47±11.80)U/L],更好地维持了L-02细胞的尿素合成功能[72 h:-0.8℃(1.01±0.14)mmol/L vs 4℃(0.66±0.09)mmol/L]及白蛋白分泌功能[72 h:-0.8℃(9.04±0.53)μg/ml vs 4℃(7.70±0.52)μg/ml].结论 与0℃及4℃相比,零下非结冰(-0.8℃)可明显提高L-02细胞存活率,降低低温损伤引起的细胞凋亡,有效的保护肝细胞尿素合成功能和白蛋白分泌功能.     

Celsior液、HTK液和UW液对心脏保存效果的实验研究

目的应用Langendorff灌注模型低温灌注离体鼠心6h,检验器官保存液Celsior液、HTK液和UW液对心脏保存的效果.方法实验分为3组,每组8只Wistar大白鼠.麻醉并抗凝后,快速取下鼠心并悬挂在Langendorff灌注模型上灌注,测定血流动力学基础值.分别用三种器官保存液灌注离体鼠心,在4℃下低温浸泡保存6h.重新复温、复灌,再次测定血流动力学值和冠状动脉流量,留取标本分别测定心肌水含量、心肌酶漏出量、心肌细胞ATP和CP含量和观察心肌细胞超微结构变化.结果①血流动力学恢复率,Celsior液和HTK液组均优于UW液组.②心肌酶漏出量,Celsior液和HTK液组明显低于UW液组.③ATP和CP含量,Celsior液和HTK液组高于UW液组.④超微结构变化,Celsior液组和HTK液组心肌损害最轻,UW液组心肌损害较重.结论Celsior液、HTK液和UW液对心脏保护的效果均较好,均为较合适的心肌保存液.Celsior液和HTK液对心脏保存的效果无显著差异,但均优于UW液.     

零下非结冰抑制线粒体途径相关的细胞凋亡成功保存生物人工肝用L02细胞

目的 比较常规低温(4℃及0℃)及零下非结冰温度(-0.8℃)保存L-02肝细胞时Bcl-2/Bax基因和蛋白表达的差异及与低温保存引起细胞凋亡的关系.方法 L-02细胞分为3组:-0.8C组(零下非结冰组),0°C组(0℃非结冰组),4℃组(对照组).低温保存72 h后,分别测定细胞存活率及凋亡率(流式细胞术),检测LDH、ALT释放及凋亡基因Bcl-2与Bax的mRNA及蛋白定量表达并计算Bcl-2/Bax比值.结果 零下非结冰组较0℃组及4℃组显著提高了低温保存72 h的L-02细胞存活率[(70.95％±3.33％)vs(65.9％±3.22％)、(61.02％±3.37％),均P＜0.05];降低了细胞凋亡率[(5.82％±1.68％)vs(8.53％±1.67％)、(9.40％±2.57％),均P＜0.05];抑制了LDH[(101.50±6.58) U/L vs(127.67±12.09)U/L、(150.13±11.38) U/L,均P＜0.05]与ALT释放[(6.07±0.63) U/L vs (7.00 ±0.60) U/L、(8.63±1.25) U/L,P ＜0.05];提高了L-02细胞Bcl-2基因mRNA及蛋白表达(均P＜0.05),降低了Bax基因mRNA及蛋白表达(均P＜0.05),Bcl-2/Bax指数上升(均P＜0.05).结论 同常规低温保存相比,零下非结冰可显著提高肝细胞低温保存后细胞存活率,降低低温损伤引起的细胞凋亡.零下非结冰降低了低温源性细胞凋亡的机制可能同Bcl-2基因表达增加、Bax基因表达降低即Bcl-2/Bax比值上升有关.     

常用心脏保存液及其改良方法

心脏移植是治疗终末期心力衰竭的最佳方案,但由于捐献器官的不足,心脏移植手术的开展受到极大限制。心脏保存液的改良对于扩大移植心脏供体池极为关键,该文介绍UW液、HTK液和Celsior液等3种常见的心脏保存液及其改良方法。     

支气管肺泡灌洗液肿瘤标志物检查诊断肺鳞状细胞癌价值分析

目的:探讨支气管肺泡灌洗液(BALF)及血清中鳞状细胞癌相关抗原(SCC)、可溶性细胞角蛋白19片段(CYFRA 21-1)、癌胚抗原(CEA)浓度对肺鳞状细胞癌的诊断、TNM分期及预后的临床意义。方法:选择经组织病理学和(或)细胞学确诊的40例肺鳞状细胞癌患者作为观察组,40例肺部炎性病变患者作为对照组,采用日本Pentax EPS 3500型电子支气管镜,经气管镜收集BALF,应用酶联免疫吸附法测定两组患者BALF及血清中SCC浓度,应用化学发光法测定两组患者BALF及血清中CYFRA21-1及CEA的浓度。结果:(1)观察组BALF中SCC[(49.6±15.4)vs.(2.1±0.8)μg/L,P=0.000]、CYFRA 21-1[(245.6±95.5)vs.(2.0±0.9)μg/L,P=0.000]、CEA[(15.6±5.5)vs.(3.6±1.4)μg/L,P=0.000],血清中SCC[(13.1±6.0)vs.(1.8±0.7)μg/L,P=0.000]、CYFRA 21-1[(20.4±10.3)vs.(1.9±0.9)μg/L,P=0.000]、CEA[(5.7±2.2)vs.(3.2±1.2)μg/L,P=0.000]均高于对照组,差异有统计学意义(P<0.01)。(2)观察组BALF中SCC[(49.6±15.4)vs.(13.1±6.0)μg/L,P=0.000]、CYFRA 21-1[(245.6±95.5)vs.(20.4±10.3)μg/L,P=0.000]、CEA[(15.6±5.5)vs.(5.7±2.2)μg/L,P=0.000]均高于血清,差异有统计学意义(P<0.01)。(3)观察组Ⅲ~Ⅳ期BALF中SCC[(63.8±10.4)vs.(41.9±11.9)μg/L,P=0.000]、CYFRA 21-1[(328.3±61.0)vs.(201.1±80.0)μg/L,P=0.000]、CEA[(20.5±4.0)vs.(12.9±4.2)μg/L,P=0.000]均高于Ⅰ~Ⅱ期,差异有统计学意义(P<0.01)。结论:BALF中SCC、CYFRA 21-1及CEA的检测对肺鳞状细胞癌的早期诊断有较好的临床价值,同时对临床分期、监测病情、判断预后也有一定临床价值,值得在临床上推广应用。     

康斯特停搏液对重症心脏瓣膜病患者手术中心肌保护的效果

目的比较康斯特停搏液和冷含血停搏液在重症心脏瓣膜病患者手术中对心肌保护的效果。方法选取2012年3月至2014年3月在北京军区总医院心血管外科收治的46例重症心脏瓣膜病患者,均接受体外循环支持下心脏瓣膜直视手术,所有患者均无风湿活动及凝血功能障碍。将患者随机分为观察组和对照组,每组各23例。观察组术中给予康斯特停搏液,对照组给予冷含血停搏液。记录两组患者体外循环时间、主动脉阻断时间、心脏自动复跳率、术后心律失常发生率、血管活性药物用量、呼吸机辅助时间、监护室停留时间。分别于术前和术后4 h、12 h及24 h检测患者肌酸激酶同工酶和血清肌钙蛋白I的含量。结果术中两组患者体外循环时间、主动脉阻断时间、术后心律失常发生率、呼吸机辅助时间和监护室停留时间比较,差异无统计学意义(P均0.05)。与对照组比较,观察组心脏自动复跳率升高(54.17%vs.79.17%),术后24 h多巴胺用量减少[(6.6±2.3)μg/(kg·min)vs.(5.2±2.1)μg/(kg·min)],差异有统计学意义(P均0.05)。与对照组比较,观察组术后肌酸激酶同工酶4h[(49.7±11.8)IU/L vs.(24.5±2.0)IU/L]、12 h[(83.9±18.3)IU/L vs.(31.1±2.6)IU/L]、24 h[(62.4±12.5)IU/L vs.(32.4±3.3)IU/L]下降,差异有统计学意义(P均0.05)。与对照组比较,观察组术后心肌肌钙蛋白I水平4 h[(1.20±0.13)μg/L vs.(0.21±0.04)μg/L]、12 h[(2.35±0.64)μg/L vs.(1.22±0.59)μg/L]、24 h[(1.75±0.24)μg/L vs.(0.76±0.41)μg/L]下降,差异有统计学意义(P均0.05)。结论康斯特停搏液对重症心脏瓣膜病患者术中心肌保护作用优于冷含血停搏液。     

左旋泊尼汀对离体大鼠心脏保存效果的影响

将25只成年雄性Wistar大鼠（体重350～400g）随机分为A组（对照组）及B、C、D、E组，每组5只，经麻醉和抗凝后，快速取下心脏。A组心脏悬挂在Langendorff灌注模型上K-H液恒压灌注，37℃下测定血流动力学指标；B、C、D、E组分别经主动脉灌注4℃ HTK液、UW液、HTK液＋左旋泊尼汀、UW液＋左旋泊尼汀心肌保存液，置于4℃相应的心肌保存液中保存6h；重新复温复灌。再次测定血流动力学指标，留取标本分别测定心肌含水量、心肌酶漏出量、ATP含量变化。结果 D组及E组平均左室发展压（LVDP）与B、C组比较显著升高，磷酸肌酸激酶同工酶（CK—MB）漏出量明显减少，心肌ATP含量明显增多。认为HTK液和UW液中加入左旋泊尼汀能改善离体鼠心脏的低温保存效果。     

D-二聚体在急性心肌梗死时冠状动脉血栓自溶再通的演变及意义

目的探讨D-二聚体在急性心肌梗死时冠状动脉血栓自溶再通的演变及意义。方法选择4所医院急性心肌梗死(AMI)患者80例,根据治疗方式及冠状动脉造影结果,将患者分为药物溶栓再通组(A组,29例),血栓自溶再通组(B组,30例)及非溶栓组(C组,21例)。各组在治疗前后1、2、4、8、24和48h检测D-二聚体、肌酸激酶同工酶(CK-MB)、肌钙蛋白I、凝血酶原时间等。A组采用重组组织型纤溶酶原激活剂进行静脉溶栓治疗,B组、C组静脉滴注等量生理盐水。结果 3组患者发生AMI后CK-MB和肌钙蛋白I水平均显著增高,与C组比较,A组D-二聚体浓度1、2、4、8h显著升高[(4.31±0.94)mg/L vs(0.89±0.12)mg/L,(5.21±1.06)mg/L vs(1.55±0.43)mg/L,(7.56±1.53)mg/L vs(0.93±0.12)mg/L,(4.33±0.99)mg/L vs(0.61±0.17)mg/L],B组D-二聚体浓度1、2h显著升高[(3.69±0.86)mg/L vs(0.89±0.12)mg/L,(2.39±0.66)mg/L vs(1.55±0.43)mg/L];与B组比较,A组D-二聚体浓度2、4、8、24h显著升高(P<0.05,P<0.01)。C组在相同时间点无显著变化。结论治疗AMI时,D-二聚体浓度变化在药物溶栓再通与血栓自溶再通有显著不同,可作为判断溶栓疗效的指标。     

急性冠状动脉综合征患者血清基质金属蛋白酶2及胱抑素C水平的临床意义

目的探讨血清基质金属蛋白酶2(MMP-2)及胱抑素C在急性冠状动脉综合征患者中的临床意义。方法选择急性冠状动脉综合征患者80例,其中急性心肌梗死组40例,不稳定性心绞痛组40例,另选择非冠心病患者30例(对照组)。采用速率散射比浊法和酶联免疫吸附法分别检测各组血清胱抑素C、MMP-2及高敏C反应蛋白(hs-CRP)水平。结果急性心肌梗死组和不稳定性心绞痛组血清MMP-2水平明显高于对照组[(294.41±35.62)μg/L,(197.79±29.43)μg/L vs(96.09±21.96)μg/L,P<0.05],胱抑素C明显低于对照组[(0.63±0.09)mg/L,(0.76±0.07)mg/L vs(0.88±0.07)mg/L,P<0.05]。直线相关分析显示,血清MMP-2与hs-CRP呈正相关,而胱抑素C与hs-CRP呈负相关。结论血清MMP-2及胱抑素C均参与急性冠状动脉综合征的发生、发展;血清MMP-2及胱抑素C可能成为急性冠状动脉综合征早期预测及危险分层的重要指标。     

Histidine-tryptophan-ketoglutarate solution versus University of Wisconsin solution in adult-to-adult living donor liver transplantation: A propensity score matching analysis from mainland China

To compare the difference between University of Wisconsin (UW) solution and histidine-tryptophan-ketoglutarate (HTK) solution in adult living donor liver transplantation (LDLT).This study included LDLT patients at the Liver Transplantation Center of West China Hospital of Sichuan University from November 2001 to June 2018. These patients were classified into 2 groups depending on the use of the different preservation solutions, and the confounding factors between the 2 groups were eliminated by propensity score matching. Finally, the incidence of complications; serum examination at postoperative days 1, 3, 5, 7, 14, 21, and 30; and the overall survival rate of the 2 groups were compared to observe whether there were any differences between the 2 preservation solutions.Of the 298 patients we screened, 170 were treated with UW solution and 128 with HTK solution. After propensity score matching, 106 pairs of patients were selected. In the comparison of the 2 groups, the length of intensive care unit stay in the UW group was significantly longer than that in the HTK group (P = .022), but there was no difference in the total length of hospital stay between the 2 groups (P = .277). No statistically significant difference was observed in the 2 groups in terms of the incidence of complications or postoperative examinations. However, the incidence of early allograft dysfunction in the HTK group was slightly lower than that in the UW group (HTK: UW = 14.1%: 20.7%), although the difference was not statistically significant. In terms of the overall survival rate, the 1, 3, and 5-year survival rates of the HTK group were 85.5%, 70.2%, and 65.1%, respectively, while the 1, 3, and 5-year survival rates of the UW group were 83.1%, 67.2%, and 59.8%, respectively, and there was no significant difference between the 2 groups.In conclusion, our study shows that UW solution and HTK solution are equivalent in perioperative safety, the recovery of transplanted liver function, the occurrence of postoperative complications and overall survival and can be safely and effectively applied in adult LDLT. If economic factors are taken into account, HTK can save costs to a certain extent.     

改良HCA肾保存液对肾脏低温保存效果的动物实验研究

目的:探讨改良高渗枸橼酸盐嘌呤肾保存液(HCA)对离体肾脏的低温保存效果。方法:将36只雄性草犬随机分为6组，分别用改良HCA(mHCA)液、Uw液(uNIVERSITY wISCOSIN器官保存液)、HCA液对其离体肾脏进行保存，并于24、48小时后观察肾脏皮质线粒体呼吸控制率(RCR)、细胞内ATP含量、pH值以及丙二醛(MDA)含量；比较肾脏移植前后血肌酐变化。结果肾脏保存24小时后，各项检测指标与移植前比较无明显差异，48小时后，mHCA液组与UW液组血肌酐差异无显著性，但均明显低于HCA液组；肾脏细胞RCR、ATP含量，mHCA液组与UW液组差异无显著性，但均高于HCA液组，mHCA液组与UW液组MDA明显降低，mHCA液组pH最高。结论:mHCA液能明显提高肾脏的低温保存效果，延长肾脏保存时间。     

Usefulness of sodium hyaluronate solution in colorectal endoscopic mucosal resection

Background: In endoscopic mucosal resection (EMR), it is essential to inject submucosal fluid to prevent complications and ensure safe and complete en bloc resection of tumors. Sodium hyaluronate (SH) solution, which is effective in forming and maintaining a mucosal lift and is innocuous to mucosal tissue, is considered a useful injection solution for endoscopic submucosal dissection, a procedure associated with a high risk of perforation. This study was undertaken to assess the usefulness of this solution in EMR. Methods: Ninety‐four patients with colorectal tumors of ≤20 mm in diameter were enrolled for this study and randomized to a SH solution group (0.2% two‐fold diluted MucoUp) or to a normal saline group (control). Ease of EMR was primarily assessed based on ease of submucosal injection, ease of snaring and injection time. Results: SH solution was superior to normal saline for ease of submucosal injection (57 ± 0.7 vs 50 ± 0.7; P < 0.05), and it showed better results for ease of snaring with less variability (63 ± 0.8 vs 51 ± 1.0; P < 0.05). The mean injection time was similar between the two groups (3.0 ± 9.0 s and 3.0 ± 2.7 s, respectively). Post‐procedural hemorrhage occurred in 7% patients (3/46) injected with SH solution and in 6% of patients (3/48) in the control group; there was no significant difference between the groups. Conclusions: Use of two‐fold diluted MucoUp facilitated colorectal EMR.     

Extended storage of platelets in SSP platelet additive solution

BACKGROUND AND OBJECTIVES: The aim of this study was to investigate the effects of extended storage of pooled random platelets in SSP+ additive solution (MacoPharma). MATERIALS AND METHODS: Eight buffy coat-derived, pooled, leucoreduced platelet concentrates were prepared in 75% SSP+, 25% plasma using Fresenius/NPBI Composelect thrombocyte polishing filter (TPF) systems. Platelet concentrates were stored for 19 days in polyolefin storage bags and samples for in vitro analysis were taken at various time-points during storage. RESULTS: Platelet yields were lower than seen routinely when platelets are prepared in 100% plasma. The in vitro quality of the platelets stored in SSP+ was maintained until day 9. Glucose was depleted by day 12 and this was accompanied by a rapid fall in pCO2, a rise in pO2 and a cessation of lactate production. ATP and bicarbonate concentrations fell, the platelets began to swell and the ability to swirl decreased. Soluble P-selectin, glycocalicin, and regulated on activation, normal, T-cell expressed, and secreted (RANTES) concentrations increased, as did P-selectin expression. Loss of platelets and an increase in lacate hydrogenase concentration indicated that lysis had occurred. However, the pH remained between 6.4 and 7.4. CONCLUSIONS: The results suggest that SSP+ could be used for platelet storage for up to 9 days. However, the preparation of platelets in the additive requires some optimization. In vivo studies are required to confirm these in vitro results.     

地高辛口服液在兔体内药动学研究

目的测定地高辛口服溶液在兔体内的药动学参数，计算相对于片剂生物利用度。方法新西兰兔8只．雌雄各半，分为两组，分别灌服地高辛口服液和地高辛片剂60μg／kg。给药后于耳缘静脉采血0．7ml。2周后，两组互换给药剂型，采血后血样经离心处理后取血清用荧光偏振免疫分析法测定血药浓度：使用DAS2．0程序计算药动学参数，用SPSS11．0进行统计学处理，并进行生物等效性评价。结果地高辛口服液的药动学参数为：AUC0-24h（11．5±3.5）μg·h·L^-1，Tmax（1．0±0.3）h，Cmax（1．8±1．1）μg·L^-1，t1/2（6．2±3．1）h。2种制剂药动学参数除Tmax外，差异均无统计学意义（P〉0．05）；地高辛口服液的相对片剂的生物利用度为（96±18）％。结论地高辛口服液比片剂在兔体内吸收更快；2种制剂具基本生物等效性。     

新型肾脏保存液低温保存后犬肾移植效果评价

目的建立犬自体肾移植模型，评价经新型肾脏保存液（HCA-Ⅱ）低温保存后的犬肾移植效果。方法60只杂种犬随机分为A（H-CA液，保存48h）、B（HCA—I液，保存48h）、C（UW液，保存48h）、D（H-CA液，保存72h）、E（HCA-Ⅱ液，保存72h）、F（UW液，保存72h）等六组。切取左肾，灌洗并放入该保存液保存。左肾动脉与右侧髂外动脉端端吻合，静脉与右侧髂外静脉端侧吻合，输尿管与膀胱抗反流吻合，同时切除右侧肾脏。检测移植前后肾功能指标。结果手术成功率95％，HCA-Ⅱ液各组术后血肌酐的峰值均低于H-CA液组，且血肌酐恢复正常的时间也较H—CA液组早（P〈0．05）；以上各指标均与UW液组无明显差别（P〈0．05）。结论HCA-Ⅱ肾脏保存液对供肾的保存效果明显好于H—CA保存液，可安全保存犬肾72h。     

比较两种胶体预充液对婴幼儿心脏直视手术治疗效果的临床研究

目的:对比体外循环(extracorporeal circulation,ECC)中6%羟乙基淀粉(HES)130/0.4与3.3%白蛋白(HA)预充对心脏手术患儿围术期血浆胶体渗透压(plasmn colloid osmotic pressure,COP)、液体平衡、肾功能及术后容量治疗的影响。方法:选择美国麻醉医师协会(ASA)Ⅰ-Ⅱ级,5～10 kg患儿行心内直视手术60例,随机分为两组,分别采用6%HES 130/0.4(HES:n=30)和3.3%HA(HA:n=30)进行体外循环预充。观察患儿临床恢复情况、围术期各时点血浆胶体渗透压变化情况、各种液体出入量、出血量和血制品使用情况。结果:HES组ECC预充液、ECC中及手术结束时COP均明显高于HA组(P<0.01);至ICU 6 h,两组COP均恢复至术前水平。ECC中HES组液体总入量明显低于HA组[(2.8±4.1)vs.(6.2±4.4)mL/kg,P<0.01],ECC后HES组输血量明显低于HA组[(27±34)vs.(59±34)mL,P<0.01]。两组血肌酐变化无差异。结论:6%HES 130/0.4能有效维持ECC中COP,减少液体正平衡及减少输血,因此6%HES 130/0.4可以替代3.3%HA于婴幼儿心内直视术ECC中预充使用。     

全自动蛋白分析仪BN-100缓冲液、稀释液国产化研究

目的 实现全自动特种蛋白分析仪试剂国产化。方法 对原装试剂进行理化分析,择最佳配方,采用进口和自行研制的缓冲液、稀释液（自研试剂）,在同样条件下按仪器操作规程于BN-100全自动免疫分析仪上对正常人标本、患者标本、原装质控物进行对比测定。结果 自研试剂的理化指标（pH、电导率及渗透压）与进口试剂相近;对德灵原装高、中、低值质控物,分别用进口试剂和自研试剂进行测定,其相关系数r均〉0．98;患者标本的相关性：IgG的相关方程y=1．0374x-0．28,r=0．998,IgA为Y=1．0111x-0．0594,r=0．989,IgM为Y=0．987x-0．0404,r=0．987;复性测定结果IgG、IgA、IgM结果自由度（v）均〈3％。结论 自研试剂可代替原机进口试剂在全自动蛋白分析仪上进行IgG、IgA、IgM检测。